MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Tumor cells overexpress PD-L1 (programmed death-1 ligand 1) to evade immune surveillance.
• Targeting PD-L1/PD1 interactions is a key cancer immunotherapy strategy.
• Understanding PD-L1 regulation is crucial for enhancing treatment efficacy.

Purpose of the Study:

• To identify molecular regulators of PD-L1 overexpression in prostate cancer.
• To investigate the role of histone methyltransferase MLL3 (mixed-lineage leukemia protein 3) in PD-L1 regulation.
• To explore MLL3 as a potential therapeutic target for overcoming immune evasion.

Main Methods:

• Analysis of MLL3 and PD-L1 expression in clinical cancer tissues (TCGA, Xiangya Hospital).
• Chromatin immunoprecipitation assays to assess MLL3 binding to the PD-L1 enhancer.
• Assessment of H3K4me1 and Pol II Ser-5p levels at PD-L1 regulatory regions.
• In vivo studies using mouse xenograft models to evaluate the impact of MLL3 depletion on tumor growth and immunotherapy response.

Main Results:

• MLL3 and PD-L1 are co-expressed and correlated in metastatic prostate cancer tissues.
• MLL3 directly binds to the enhancer region of PD-L1.
• MLL3 depletion reduces H3K4me1 and Pol II recruitment to PD-L1 regulatory elements, decreasing PD-L1 transcription.
• MLL3 inhibition impairs tumor growth and reduces response to PD-L1 antibody treatment in vivo.

Conclusions:

• MLL3 is a critical regulator of PD-L1 transcription in prostate cancer.
• MLL3 acts as a histone writer, influencing epigenetic marks at the PD-L1 locus.
• MLL3 represents a novel therapeutic target for enhancing anti-tumor immunity and overcoming resistance to PD-L1 blockade therapy.